Effects of statins vs. non-statin lipid-lowering therapy on bone formation and bone mineral density biomarkers in patients with hyperlipidemia

Bone

Volumn 46, Issue 4, 2010, Pages 1011-1015

  Chuengsamarn, Somlak ^a   Rattanamongkoulgul, Suthee ^a   Suwanwalaikorn, Somponge ^b   Wattanasirichaigoon, Somkiat ^a   Kaufman, Larry ^a  

^a SRINAKHARINWIROT UNIVERSITY   (Thailand)

^b CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

Bone markers; Bone mineral Density; Hypercholesterolemia; Osteoporosis; Statins

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; BONE MORPHOGENETIC PROTEIN 2; CARBOXY TERMINAL TELOPEPTIDE; CHOLESTEROL; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; BONE DENSITY; BONE TISSUE; CELL DIFFERENTIATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DRUG DOSE INCREASE; FEMALE; HUMAN; HYPERLIPIDEMIA; LIPOPHILICITY; MAJOR CLINICAL STUDY; MALE; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PLEIOTROPY; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

AGED; ANTILIPEMIC AGENTS; BONE DENSITY; BONE DISEASES, METABOLIC; FEMALE; GEMFIBROZIL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; OSTEOGENESIS; PATIENT SELECTION; PROSPECTIVE STUDIES; SIMVASTATIN; TREATMENT OUTCOME;

EID: 77950532155     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2009.12.023     Document Type: Article

References (35)

1. Downs J.R., Clearfield M., Weis S., Whitney E., Shapiro D.R., Beere P.A., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998, 279:1615-1622.
2. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344:1383-1389. Scandinavian Simvastatin Survival Study.
3. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., MacFarlane P.W., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N. Eng. J. Med. 1995, 333:1301-1307.
4. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N. Eng. J. Med. 1998, 339:1349-1357. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group.
5. McFarlane S.I., Muniyappa R., Francisco R., Sowers J.R. Clinical review 145: pleiotropic effects of statins: lipid reduction and beyond. J. Clin. Endocrinol. Metab. 2002, 87:1451-1458.
6. van Beek E., Pieterman E., Cohen L., Löwik C., Papapoulos S. Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem. Biophys. Res. Commun. 1999, 264:108-111.
7. Fisher J.E., Rogers M.J., Halasy J.M., Luckman S.P., Hughes D.E., Masarachia P.J., et al. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:133-138.
8. Halcox J.P.J., Deanfield J.E. Beyond the laboratory: clinical implications for statin pleiotropy. Circulation 2004, 109:II42-II48.
9. Kaji H, Kanatani M, Sugimoto T, Chihara K. Statins modulate the levels of osteoprotegerin/receptor activator of NFkappaB ligand mRNA in mouse bone-cell cultures. Hormone and Metabolic Research = Hormon-Und Stoffwechselforschung = Hormones Et Métabolisme 2005;37: 589-592.
10. Viereck V., Gründker C., Blaschke S., Frosch K.-H., Schoppet M., Emons G., et al. Atorvastatin stimulates the production of osteoprotegerin by human osteoblasts. J. Cell. Biochem. 2005, 96:1244-1253.
11. Mundy G., Garrett R., Harris S., Chan J., Chen D., Rossini G., et al. Stimulation of bone formation in vitro and in rodents by statins. Science 1999, 286:1946-1949.
12. Ghosh-Choudhury N., Mandal C.C., Choudhury G.G. Statin-induced Ras activation integrates the phosphatidylinositol 3-kinase signal to Akt and MAPK for bone morphogenetic protein-2 expression in osteoblast differentiation. J. Biol. Chem. 2007, 282:4983-4993.
13. Jadhav S.B., Jain G.K. Statins and osteoporosis: new role for old drugs. J. Pharm. Pharmacol. 2006, 58:3-18.
14. Maeda T., Matsunuma A., Kawane T., Horiuchi N. Simvastatin promotes osteoblast differentiation and mineralization in MC3T3-E1 cells. Biochem. Biophys. Res. Commun. 2001, 280:874-877.
15. Ruiz-Gaspa S., Nogues X., Enjuanes A., Monllau J.C., Blanch J., Carreras R., et al. Simvastatin and atorvastatin enhance gene expression of collagen type 1 and osteocalcin in primary human osteoblasts and MG-63 cultures. J. Cell. Biochem. 2007, 101:1430-1438.
16. Tikiz C., Unlü Z., Tikiz H., Ay K., Angin A., Onur E., et al. The effect of simvastatin on serum cytokine levels and bone metabolism in postmenopausal subjects: negative correlation between TNF-alpha and anabolic bone parameters. J. Bone Miner. Metab. 2004, 22:365-371.
17. Staal A., Frith J.C., French M.H., Swartz J., Güngör T., Harrity T.W., et al. The ability of statins to inhibit bone resorption is directly related to their inhibitory effect on HMG-CoA reductase activity. J. Bone Miner. Res. 2003, 18:88-96.
18. Dupont W., Plummer W. PS power and sample size program available for free on the Internet. Controlled. Clin. Trials 1997, 18:274.
19. Bone H.G., Kiel D.P., Lindsay R.S., Lewiecki E.M., Bolognese M.A., Leary E.T., et al. Effects of atorvastatin on bone in postmenopausal women with dyslipidemia: a double-blind, placebo-controlled, dose-ranging trial. J. Clin. Endocrinol. Metab. 2007, 92:4671-4677.
20. Bauer D.C., Mundy G.R., Jamal S.A., Black D.M., Cauley J.A., Harris F., et al. Statin use, bone mass and fracture: an analysis of two prospective studies. J. Bone Miner. Res. 1999, 14:S179.
21. Chan K.A., Andrade S.E., Boles M., Buist D.S., Chase G.A., Donahue J.G., et al. Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women. Lancet 2000, 355:2185-2188.
22. Meier C.R., Schlienger R.G., Kraenzlin M.E., Schlegel B., Jick H. HMG-CoA reductase inhibitors and the risk of fractures. JAMA 2000, 283:3205-3210.
23. Wang P.S., Solomon D.H., Mogun H., Avorn J. HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients. JAMA 2000, 283:3211-3216.
24. Reid I.R., Hague W., Emberson J., Baker J., Tonkin A., Hunt D., et al. Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial. Long-term intervention with pravastatin in ischaemic disease. Lancet 2001, 357:509-512.
25. Chung Y.S., Lee M.D., Lee S.K., Kim H.M., Fitzpatrick L.A. HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients. J. Clin. Endocrinol. Metab. 2000, 85:1137-1142.
26. Wada Y., Nakamura Y., Koshiyama H. Lack of positive correlation between statin use and bone mineral density in Japanese subjects with type 2 diabetes. Arch. Intern. Med. 2000, 160:2865.
27. Pasco J.A., Kotowicz M.A., Henry M.J., Sanders K.M., Nicholson G.C. Statin use, bone mineral density, and fracture risk: Geelong Osteoporosis Study. Arch. Intern. Med. 2002, 162:537-540.
28. Montagnani A., Gonnelli S., Cepollaro C., Pacini S., Campagna M.S., Franci M.B., et al. Effect of simvastatin treatment on bone mineral density and bone turnover in hypercholesterolemic postmenopausal women: a 1-year longitudinal study. Bone 2003, 32:427-433.
29. Lupattelli G., Scarponi A.M., Vaudo G., Siepi D., Roscini A.R., Gemelli F., et al. Simvastatin increases bone mineral density in hypercholesterolemic postmenopausal women. Metabolism 2004, 53:744-748.
30. Rosenson R.S., Tangney C.C., Langman C.B., Parker T.S., Levine D.M., Gordon B.R. Short-term reduction in bone markers with high-dose simvastatin. Osteoporos. Int. 2005, 16:1272-1276.
31. Chan M.H., Mak T.W., Chiu R.W., Chow C.C., Chan I.H., Lam C.W. Simvastatin increases serum osteocalcin concentration in patients treated for hypercholesterolaemia. J. Clin. Endocrinol. Metab. 2001, 86:4556-4559.
32. Braatvedt G.D., Bagg W., Gamble G., Davidson J., Reid I.R. The effect of atorvastatin on markers of bone turnover in patients with type 2 diabetes. Bone 2004, 35:766-770.
33. Stein E.A., Farnier M., Waldstreicher J., Mercuri M. Effects of statins on biomarkers of bone metabolism: a randomised trial. Nutr. Metab. Cardiovasc. Dis. 2001, 11:84-87.
34. Bjarnason N.H., Riis B.J., Christiansen C. The effect of fluvastatin on parameters of bone remodeling. Osteoporos. Int. 2001, 12:380-384.
35. Uzzan B., Cohen R., Nicolas P., Cucherat M., Perret G.Y. Effects of statins on bone mineral density: a meta-analysis of clinical studies. Bone 2007, 40:1581-1587.